Search
Invitrogen
Laminin beta-2/gamma-1 Monoclonal Antibody (SPM277)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Additional Information:
{{banner.description}}
产品信息
MA1-21236
应用
建议稀释比
已发表文章
产品规格
宿主/亚型
Rat
/ IgG1
分类
Monoclonal
类型
Antibody
克隆号
SPM277
抗原
Tissue / cell preparation. (Murine EHS laminin preparation)
偶联物
Unconjugated
Unconjugated
Unconjugated
形式
Liquid
浓度
0.1 mg/mL
规格
700 µg
保存条件
4°C, do not freeze
运输条件
Wet ice
产品详细信息
MA1-21236 detects Laminin B2 gamma 1 in Human and Mouse samples.
MA1-21236 has been successfully used in Immunofluorescence, Immunohistochemistry (Paraffin), Immunoprecipitation and Western Blot procedures.
MA1-21236 immunogen corresponds to Tissue / cell preparation. (mouse EHS laminin preparation).
靶标信息
Laminins are large heterotrimeric, noncollagenous glycoproteins composed of alpha, beta, and gamma chains. They are ubiquitously present in basement membrane (BM) along with entactin/nidogen (EN), collagen type IV (CIV), and large heparan sulfate proteoglycan (HSPG), which interact specifically with each other to form a continuous and regular BM. Alterations of BM integrity, from local discontinuities up to complete loss, are described in many types of human and animal epithelial neoplasms.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
